Fig. 2: Mean serum concentration-time profile of encelimab dose 1 in parts 1A and 1B. | BJC Reports

Fig. 2: Mean serum concentration-time profile of encelimab dose 1 in parts 1A and 1B.

From: CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Fig. 2

Mean serum concentration time profile plotted on a linear scale (a, c) and semi-logarithmic scale (b, d) for encelimab dose 1 in part 1A (a, b) and part 1B (c, d); both encelimab monotherapy. Data points show mean ± standard deviation.

Back to article page